Loading…
Employees: 58
Size Rezolute (RZLT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $375M, the 2910th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.88 on 6 Nov 2026.
Performance Over six months the shares gained 20.9%, against -22.3% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 19 in its peer set.
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$31,000 | -$31,000 | -$31,000 | -$36,000 | -$382,000 |
| EBITDA | -$82.9M | -$82.9M | -$79.9M | -$70.4M | -$55.6M |
| Net income | -$77.6M | -$77.6M | -$74.4M | -$68.5M | -$51.8M |
| Free cash flow | -$64.6M | -$64.6M | -$69.1M | -$57.4M | -$44.6M |
| Capital expenditure | $0 | $0 | $0 | $0 | $153,000 |
| Total debt | $934,000 | $934,000 | $1.61M | $2.23M | $2.48M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RZLT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.4% | -10.9% | 6th lowest of 20 |
| 6-month return | +20.9% | -22.3% | 3rd highest of 19 |
| Distance from 52-week high | -66.1% | -38.2% | 5th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | 2.0× | 9.0% | -11.3% |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | 1.5× | n/a | n/a |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | 8.3× | 16.3% | -14.0% |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | 1.1× | 4.2% | +3.1% |
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | 46.9× | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | 1.8× | 13.2% | +6.5% |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | 22.0× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 0.5× | 10.5% | +4.2% |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | 324.5× | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | 5.8× | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 3.2× | -6.6% | +24.8% |